posted on 2022-09-14, 04:49authored byEB Brazel, A Tan, SL Neville, AR Iverson, Saumya Udagedara, BA Cunningham, Mwilye Sikanyika, DMP De Oliveira, B Keller, L Bohlmann, IM El-Deeb, K Ganio, BA Eijkelkamp, AG McEwan, M von Itzstein, Megan MaherMegan Maher, MJ Walker, JW Rosch, CA McDevitt
Streptococcus pneumoniae is the primary cause of community-acquired bacterial pneumonia with rates of penicillin and multidrug-resistance exceeding 80% and 40%, respectively. The innate immune response generates a variety of antimicrobial agents to control infection, including zinc stress. Here, we characterize the impact of zinc intoxication on S. pneumoniae, observing disruptions in central carbon metabolism, lipid biogenesis, and peptidoglycan biosynthesis. Characterization of the pivotal peptidoglycan biosynthetic enzyme GlmU indicates a sensitivity to zinc inhibition. Disruption of the sole zinc efflux pathway, czcD, renders S. pneumoniae highly susceptible to β-lactam antibiotics. To dysregulate zinc homeostasis in the wild-type strain, we investigated the safe-for-human-use ionophore 5,7-dichloro-2-[(dimethylamino)methyl]quinolin-8-ol (PBT2). PBT2 rendered wild-type S. pneumoniae strains sensitive to a range of antibiotics. Using an invasive ampicillin-resistant strain, we demonstrate in a murine pneumonia infection model the efficacy of PBT2 + ampicillin treatment. These findings present a therapeutic modality to break antibiotic resistance in multidrug-resistant S. pneumoniae.
Funding
This work was supported by the National Health and Medical Research Council (NHMRC) Project Grants 1080784 and 1140554 to C.A.M. and M.J.M., 1176180 and 1194130 to M.J.W., 1071659 to M.J.W. and M.V.I., and 1122582 to C.A.M. and the Australian Research Council (ARC) Discovery Project Grant DP170102102 to C.A.M. This work was also supported by the National Institutes of Health grants (1U01AI124302 and 1RO1AI110618) to J.W.R. S.L.N. is an NHMRC Early Career Research Fellow (1142695) and C.A.M. and M.J.M. are ARC Future Fellows (FT170100006 and FT180100397, respectively). Part of this study was carried out using the MX2 beamline at the Australian Synchrotron, which is part of Australian Nuclear Science and Technology Organization (ANSTO) and made use of the Australian Cancer Research Foundation (ACRF) Detector. We thank the beamline staff for their enthusiastic and professional support, Prof. Jan-Willem Veening (University of Lausanne) for provision of the hlpA fluorescent construct and Prof. Michael Caparon (Washington University) for the pABG5-3 mini plasmid.
History
Publication Date
2022-01-11
Journal
Cell Reports
Volume
38
Issue
2
Article Number
110202
Pagination
18p.
Publisher
Cell Press
ISSN
2211-1247
Rights Statement
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).